Skip to content

ACC/AHA 2026: dyslipidaemia

International ACC/AHA Current

2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia

Circulation. 2026;153:e1154–e1276
DOI 10.1161/CIR.0000000000001423 · Summary checked against the source: 2026-11

Read or download the original

Replaces the 2018 AHA/ACC cholesterol guideline. The big changes: LDL-C goals are back, risk is estimated with the PREVENT equations, Lp(a) is measured once in everyone, and a very-high-risk group gets an LDL-C goal <55 mg/dL.

At a glance

  1. Screen with a lipid profile from age 19, then at least every 5 years; children once at 9–11 years. [1, B-NR · e1164]
  2. Measure Lp(a) at least once in every adult. High = ≥125 nmol/L (≥50 mg/dL). [1, B-NR · e1168; e1234]
  3. Estimate 10-year risk with PREVENT-ASCVD (age 30–79, LDL-C 70–189 mg/dL): low <3%, borderline 3–<5%, intermediate 5–<10%, high ≥10%. [1, B-NR · e1183]
  4. Goals: primary prevention <100 (borderline or intermediate) or <70 mg/dL (high risk, diabetes with risk factors); ASCVD <70; very-high-risk ASCVD <55 mg/dL. [e1192–e1208]
  5. CAC score settles uncertain decisions: CAC 0 may defer therapy; CAC >0 means start; ≥1000 treat like very high risk. [e1189–e1213]
  6. Lipid profile 4–12 weeks after starting or changing therapy, then every 6–12 months. [1, A · e1169]

Measurement

  • Fasting or non-fasting profile for baseline; fasting if TG ≥400 mg/dL or a TG disorder is suspected. [1, B-NR · e1166]
  • Calculate LDL-C with the Martin/Hopkins or Sampson/NIH equation, not Friedewald. Report non-HDL-C. [1, B-NR · e1166]
  • ApoB is reasonable to guide intensification on therapy, especially with diabetes, CKM syndrome or high TG. [2a, B-NR · e1167]
  • With TG ≥150, prefer non-HDL-C or apoB to LDL-C for decisions. [2a, B-NR · e1228]

Primary prevention

10-year PREVENT risk Treatment LDL-C goal Grade
Low <3% (age 30–59), LDL <160, 30-year risk <10% Healthy lifestyle 1, A
Low, but LDL 160–189 or 30-year risk ≥10% Moderate-intensity statin reasonable 2a, C-LD
Borderline 3–<5% Consider risk enhancers; moderate statin if treating (≥30–49% LDL fall) <100 (non-HDL <130) 2a
Intermediate 5–<10% At least moderate-intensity statin <100 (non-HDL <130) 1, A
High ≥10% High-intensity statin (≥50% LDL fall); add ezetimibe, then a PCSK9 mAb or bempedoic acid if not at goal <70 (non-HDL <100) 1, A; 2a; 2b

Adapted from ACC/AHA 2026 recommendations 5.1.1–5.1.11 [e1192]

  • Borderline risk: risk enhancers, and hsCRP ≥2 mg/L twice, favour treatment; consider reproductive history (early menopause, pre-eclampsia, gestational diabetes, preterm delivery). [2a · e1186, e1189]
  • CAC for uncertain decisions (intermediate, or selected borderline): CAC 0 with a preference to avoid drugs may defer therapy; CAC >0 start, especially if ≥100 or ≥75th percentile. Incidental CAC on any CT means atherosclerosis is present. [1, B-R; 2a; 1, B-NR · e1189–e1190]
CAC score (AU) Treatment LDL-C goal
≥1000 Statin-based, ≥50% fall <55 (1, B-NR)
300–999 Statin-based, ≥50% fall <70 (1, B-R); <55 reasonable
100–299 or ≥75th percentile Statin-based, ≥50% fall <70 (1, B-R)
1–99 and <75th percentile Moderate-intensity statin reasonable <100 (2a, B-R)

Adapted from ACC/AHA 2026 section on CAC [e1213]

Special groups

Group Recommendation Grade
LDL-C ≥190 mg/dL Exclude secondary causes; maximally tolerated statin; add ezetimibe, PCSK9 mAb or bempedoic acid as needed; inclisiran reasonable if LDL ≥100 despite statin ± ezetimibe 1; 2a
Familial hypercholesterolaemia Panel-based genetic testing; don't use general-population risk scores; cascade screening of relatives from age 2 1, B-NR; 3: Harm
Homozygous FH Lipid specialist; statin + ezetimibe ± PCSK9 mAb; evinacumab or lomitapide; apheresis 1; 2b
Diabetes, age 40–75 Moderate-intensity statin, goal <100; high-intensity, goal <70, with multiple risk factors 1, A; 2a, B-R
CKD stage 3+, age 40–75 Moderate statin ± ezetimibe; with ASCVD, high-intensity, goal <55 1, B-R
Haemodialysis Continuing a statin may be reasonable 2b
HIV on ART, age 40–75 Statin 1, B-R
Older than 75 Moderate statin may be reasonable with life expectancy ≥2.5 years; CAC can help 2b
Life expectancy <1 year Stopping may be reasonable 2b

Adapted from ACC/AHA 2026 [e1197–e1225]

Clinical ASCVD

Very high risk = ≥2 major ASCVD events (ACS in the past 12 months, previous MI, ischaemic stroke, symptomatic PAD), or 1 major event + ≥2 high-risk features (age ≥65, CABG or PCI, smoking, diabetes, heart failure, hypertension, LDL ≥100 despite statin + ezetimibe). [e1163]

Not very high risk Very high risk
Statin High-intensity, ≥50% fall (1, A) High-intensity, ≥50% fall (1, A)
LDL-C goal <70 mg/dL (non-HDL <100); <55 reasonable <55 mg/dL (non-HDL <85)
Add-on Ezetimibe, PCSK9 mAb or bempedoic acid reasonable (2a) Ezetimibe and/or PCSK9 mAb should be added (1, A); bempedoic acid or inclisiran reasonable (2a)

Adapted from ACC/AHA 2026 recommendations for clinical ASCVD [e1208]

Triglycerides and Lp(a)

TG (fasting) Management
150–499 mg/dL Lifestyle (low added sugar and refined carbohydrate, less alcohol, 5–10% weight loss, exercise); treat secondary causes; use PREVENT for statin decisions
ASCVD or diabetes + risk factor, LDL <100 on a statin: icosapent ethyl may be considered (2b)
500–999 mg/dL No alcohol, limit fat; fibrate or omega-3 reasonable
≥1000 mg/dL Very low-fat diet, no alcohol or added sugar, dietitian; risk of pancreatitis; olezarsen for familial chylomicronaemia (1, B-R)

Adapted from ACC/AHA 2026 [e1172–e1228]

  • High Lp(a) (≥125 nmol/L): control all other risk factors early; with ASCVD not at goal, add a PCSK9 mAb. Cascade-test relatives. [1 · e1168, e1234]

Statin intolerance and safety

  • Assess muscle symptoms for secondary causes; discuss the higher risk of stopping; rechallenge with a lower dose, another statin or intermittent dosing; use bempedoic acid, ezetimibe or a PCSK9 mAb when goals aren't met. [1 · e1235]
  • New diabetes on a statin: continue the statin. Stable chronic liver disease (including MASLD): statins are reasonable. [1, A; 2a, B-R · e1238]
  • Pregnancy: stop statins 1–2 months before trying to conceive unless high risk (FH or ASCVD may continue after discussion); bile acid sequestrants are reasonable in pregnancy; fibrates (after the first trimester) or omega-3 for TG ≥500. [e1220]

Clinical pearls

  • Goals are back: <100 (moderate risk), <70 (high risk or ASCVD), <55 (very-high-risk ASCVD).
  • PREVENT replaces the Pooled Cohort Equations; thresholds 3%, 5%, 10%.
  • Lp(a) once in every adult.
  • CAC 0 can defer statins; CAC ≥100 means treat.
  • Add-on order: ezetimibe, then PCSK9 mAb (or bempedoic acid, inclisiran).

Classes and levels of evidence

How ACC/AHA 2026 grades its recommendations. Adapted from ACC/AHA 2026 Table 3 [e1162]. Hover over any class or level cited on this page to see what it means.

Class Strength Meaning Wording used
Class 1 Strong Benefit >>> risk is recommended; is indicated, useful, effective or beneficial; should be performed or administered
Class 2a Moderate Benefit >> risk is reasonable; can be useful, effective or beneficial
Class 2b Weak Benefit ≥ risk may or might be reasonable; may or might be considered; usefulness is unknown, unclear or uncertain
Class 3: No benefit Moderate Benefit = risk (generally used only with level A or B) is not recommended; is not indicated, useful or effective; should not be performed or administered
Class 3: Harm Strong Risk > benefit potentially harmful; causes harm; associated with excess morbidity or mortality; should not be performed or administered
Level Meaning
Level A High-quality evidence from more than one RCT, meta-analyses of high-quality RCTs, or one or more RCTs corroborated by high-quality registry studies
Level B-R (randomised) Moderate-quality evidence from one or more RCTs, or meta-analyses of moderate-quality RCTs
Level B-NR (non-randomised) Moderate-quality evidence from one or more well-designed, well-executed non-randomised, observational or registry studies, or meta-analyses of such studies
Level C-LD (limited data) Randomised or non-randomised observational or registry studies with limitations of design or execution, meta-analyses of such studies, or physiological or mechanistic studies in humans
Level C-EO (expert opinion) Consensus of expert opinion based on clinical experience

Class (strength) and level (quality) are judged independently, so any class can pair with any level. A level C recommendation isn't necessarily weak: many important clinical questions can't be tested in trials, yet there may be clear clinical consensus.